Logotype for Immuneering Corporation

Immuneering (IMRX) Study update summary

Event summary combining transcript, slides, and related documents.

Logotype for Immuneering Corporation

Study update summary

12 Nov, 2026

Atebimetinib rationale and pipeline

  • Oral, once-daily third-generation MEK inhibitor designed for deep, transient pathway inhibition followed by a recovery window; intended to improve tolerability and preserve body mass.

  • Combination programs span chemotherapy, CLDN18.2-targeted agents, PRMT5 inhibitors, G12D/G12V inhibitors and immunotherapy.

  • Atebimetinib plus cemiplimab study expected to dose its first patient by year-end; an NSCLC anti-PD-1 program is also planned to start before year-end.

Pancreatic cancer

  • Interim Phase 2 analysis of 55 patients treated at 320 mg once daily showed median overall survival of 17.3 months; 84% of evaluable patients maintained or gained weight at 3 months. H1 2027 update planned.

  • MAPKeeper 301, a global Phase 3 trial of atebimetinib plus gemcitabine/nab-paclitaxel in first-line metastatic disease, began dosing and was enrolling ahead of schedule; topline results expected mid-2028.

  • Two Astellas-sponsored studies will test investigational CLDN18.2 combinations: one adds a CLDN18.2 candidate to atebimetinib plus mGnP in first-line disease; the other tests a chemotherapy-free regimen in previously treated disease.

  • Astellas will sponsor and conduct the studies, and atebimetinib supply will be provided; each party retains development and commercialization rights to its respective investigational medicines. The collaboration is the fourth pharma partnership.

Anaplastic thyroid cancer

  • Planned Phase 2 study evaluates second-line atebimetinib plus carboplatin and pemetrexed in MAPK-altered ATC after first-line standard treatment; cohorts address BRAF V600E and other eligible disease.

  • Design includes a six-patient safety run-in, followed by cohorts of ~29 patients each; atebimetinib dose is 320 mg. Primary endpoint is objective response rate.

  • Secondary endpoints include duration of response, disease control rate, progression-free survival, safety and overall survival; study was designed with investigators from four leading ATC centers and is considered potentially registrational.

  • IND submission planned by year-end; pending regulatory clearance, first dosing targeted for mid-2027, with top-line results potentially 12–18 months after dosing begins.

  • MAP kinase pathway drivers occur in most ATC cases, including ~40% with BRAF mutations and 33% with other mutations; second-line options remain limited.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Immuneering